Symbols

DAWN

Day One·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

FDA Approved

RSI Overbought

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DAWN

Day One Biopharmaceuticals, Inc.

A clinical-stage biopharmaceutical company that develops therapies & immno-oncology for cancers

Industry

Pharmaceutical

Established Date

Listing Date

05/27/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

178

Fiscal Year Ends

12-31

Website

www.dayonebio.com

Security Type

Common stock

Office address

1800 Sierra Point Parkway Suite 200 Brisbane CA 94005

Business

Introduction

Day One Biopharmaceuticals, Inc., was incorporated in Delaware as a limited liability company in November 2018. As a commercial-stage biopharmaceutical company, the company focuses on the development of first-of-its-kind or best-in-class medicines for childhood and adult diseases. Day One adopts a search and development strategy to identify, acquire and advance drug programs, and its first commercialized product is tovorafenib, an oral, blood-brain barrier penetrating, highly selective type II RAF kinase inhibitor.

Company Financials

EPS

DAWN has released its 2025 Q4 earnings. EPS was reported at -0.21, versus the expected -0.16, missing expectations. The chart below visualizes how DAWN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DAWN has released its 2025 Q4 earnings report, with revenue of 53.72M, reflecting a YoY change of 83.92%, and net profit of -21.28M, showing a YoY change of 67.62%. The Sankey diagram below clearly presents DAWN's revenue sources and cost distribution.